Nonalcoholic Fatty Liver Disease in HIV‐Infected Patients Referred to a Metabolic Clinic: Prevalence, Characteristics, and Predictors
Open Access
- 15 July 2008
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 47 (2), 250-257
- https://doi.org/10.1086/589294
Abstract
Background. The prevalence and predictors of nonalcoholic fatty liver disease (NAFLD) in human immunodeficiency virus (HIV)-infected highly active antiretroviral therapy-experienced patients and the association of NAFLD with risk of cardiovascular disease and subclinical atherosclerosis are unknown. Methods. We performed a cross-sectional observational study. NAFLD was defined by liver-spleen attenuation values of Results. We enrolled 225 patients; 163 (72.4%) were men. Mean (±SD) HIV infection duration was 147 ± months, and mean (60 ± SD) body mass index (calculated as weight in kilograms divided by the square of height in meters) was 23.75 ± 3.59. NAFLD was diagnosed in 83 patients (36.9% of the total cohort). The following variables were significantly associated with NAFLD in univariate analyses: sex, waist circumference, body mass index, cumulative exposure to nucleoside reverse-transcriptase inhibitors, visceral adipose tissue, homeostasismodel assessment of insulin resistance index, serum alanine and aspartate aminotransferase levels, and ratios of total serum cholesterol to high-density lipoprotein cholesterol. Coronary artery calcium scores and a diagnosis of diabetes were not associated with NAFLD. In multivariable logistic regression analyses, factors associated (P < .001) with NAFLD were higher serum alanine to aspartate ratio (odds ratio, 4.59; 95% confidence interval, 2.09–10.08), male sex (odds ratio, 2.49; 95% confidence interval, 1.07–5.81), greater waist circumference (odds ratio, 1.07; 95% confidence interval, 1.03–1.11), and longer nucleoside reverse-transcriptase inhibitor exposure (odds ratio, 1.12 per year of exposure; 95% confidence interval, 1.03–1.22). Conclusions. NAFLD is common among HIV-infected persons who have the traditional risk factors for NAFLD (elevations in serum alanine level, male sex, and increased waist circumference) apparent. Exposure to nucleoside reverse-transcriptase inhibitors was an independent risk factor for NAFLD, with an 11% increase in the odds ratio for each year of use.This publication has 35 references indexed in Scilit:
- Non-alcoholic fatty liver disease and increased risk of cardiovascular diseaseAtherosclerosis, 2007
- GI Epidemiology: nonalcoholic fatty liver diseaseAlimentary Pharmacology & Therapeutics, 2007
- Non‐alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickensDiabetic Medicine, 2007
- Association of Cardiorespiratory Fitness, Body Mass Index, and Waist Circumference to Nonalcoholic Fatty Liver DiseaseGastroenterology, 2006
- Body mass index and waist circumference in non‐alcoholic fatty liver diseaseJournal of Human Nutrition and Dietetics, 2005
- Metabolic Significance of Nonalcoholic Fatty Liver Disease in Nonobese, Nondiabetic AdultsArchives of Internal Medicine, 2004
- Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic ConferenceJournal of Hepatology, 2003
- Nonalcoholic Fatty Liver DiseaseThe New England Journal of Medicine, 2002
- Imaging of Hepatic SteatosisSeminars in Liver Disease, 2001
- Fatty liver hepatitis (steatohepatitis) and obesity: An autopsy study with analysis of risk factorsJournal of Hepatology, 1990